SCHEMBL30796771

SCHEMBL30796771

Nc1nnc(Cl)cc1N1CC2CCC(C1)N2c1ncc(N2CCN(C(=O)OCc3ccccc3)CC2)cn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ TMEM97 Q5BJF2 6/20 0.41
▸ SIGMAR1 Q99720 6/20 0.41
▸ HTR1A P08908 3/20 0.41
▸ HRH2 P25021 3/20 0.41
▸ HRH1 P35367 3/20 0.41
▸ HRH3 Q9Y5N1 3/20 0.41
▸ ADRA2C P18825 2/20 0.41
▸ HDAC1 Q13547 2/20 0.40
▸ GRIN2B Q13224 7/20 0.40
▸ NPC1 O15118 2/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ CYP2D6 P10635 4/20 0.39
▸ CYP2C9 P11712 4/20 0.39
▸ CYP3A4 P08684 3/20 0.39
▸ ADRA2A P08913 2/20 0.39
▸ ADRA2B P18089 2/20 0.39
▸ HTR2A P28223 2/20 0.39
▸ HTR2C P28335 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30797119 1.00 SMN1; SMN2 (0.41) SMN1; SMN2CYP2C19TMEM97SIGMAR1HTR1A
SCHEMBL30797014 0.88 SMARCA2 (0.51) HDAC1
SCHEMBL30797042 0.88 SMARCA2 (0.51) HDAC1
SCHEMBL29704310 0.83 SMARCA2 (0.47) SMN1; SMN2MAPT
SCHEMBL23301307 0.83 OPRM1 (0.43) SMN1; SMN2CYP2C19TMEM97SIGMAR1HTR1A
SCHEMBL29910532 0.83 OPRM1 (0.43) SMN1; SMN2CYP2C19TMEM97SIGMAR1HTR1A
SCHEMBL30796426 0.83 OPRM1 (0.43) SMN1; SMN2CYP2C19TMEM97SIGMAR1HTR1A
SCHEMBL30797146 0.83 TRPC3 (0.43) SMN1; SMN2CYP2C19GRIN2BNPC1RAB9A
SCHEMBL30796943 0.83 SMN1; SMN2 (0.48) SMN1; SMN2CYP2C19TMEM97SIGMAR1HTR1A
SCHEMBL23304195 0.82 LTA4H (0.41) SMN1; SMN2CYP2C19TMEM97SIGMAR1HRH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4539849-A1 COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 C4 Therapeutics, Inc. (US) 2025-04-23 — — EP disclosed
WO-2023244764-A1 COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 C4 THERAPEUTICS, INC. (US) 2023-12-21 — — WO disclosed
Send feedback